Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095225 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00095225 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 122 participants.
The verdict
NCT00095225, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.
Interventions
- DRUG Avastin (bevacizumab)
- DRUG Tarceva (erlotinib HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095225
The ClinicalTrials.gov registry entry for NCT00095225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avastin (bevacizumab) is the first listed.
NCT00095225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095225 about?
NCT00095225 is a clinical study titled "A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)". This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.
What is the current status of trial NCT00095225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2004-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00095225?
The interventions under investigation include: Avastin (bevacizumab) (DRUG), Tarceva (erlotinib HCl) (DRUG).
Who is sponsoring clinical trial NCT00095225?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.